NCI-2023-08628

A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer The ACHIEVE Study

The ACHIEVE Study is a randomized Phase 3 research study comparing chemo-immunotherapy (a combination of chemotherapy and immunotherapy) against immunotherapy alone for older adults who are vulnerable and have advanced non-small cell lung cancer (NSCLC). The study involves the combination of chemotherapy (which targets rapidly dividing cancer cells) and immunotherapy (which stimulates the immune system to fight cancer cells). The study aims to determine which treatment approach provides better outcomes in terms of efficacy and safety for this specific patient population.

Phase 3: A phase 3 clinical trial is a large-scale study designed to assess the effectiveness and safety of a new medical treatment or approach compared to a standard treatment

non-small cell lung cancer (NSCLC): A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06096844

Clinical Trial Site: Einstein

To see all available clinical trials click here.